The TIDE score predicts outcomes in melanoma patients who receive first-line anti-PD1 or anti-CTLA4 therapy by mimicking two escape mechanisms of tumors (T cell dysfunction signature and T cell exclusion signature) more accurately than other biomarkers, such as PD-L1 levels and mutation load (Jiang et al., 2018). Here, CTLA4 is linked to melanoma.